EDIT Editas Medicine

Editas Medicine's Return On Capital Employed Insights

Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter. In Q4, Editas Medicin

05-19 22:07

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persis

05-18 18:54

Why Editas Medicine's Shares Fell 28.9% This Week

The company's progress for its lead therapy has been slow. What happened Shares of Editas Medicine (EDIT 9.34%), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editi

05-13 23:58

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

05-13 23:14

Editas Medicine Gets FDA Orphan Drug Designation for Blood Disorder Candidate

04:31 AM EDT, 05/13/2022 (MT Newswires) -- Editas Medicine (EDIT) said late Thursday the US Food and Drug Administration has granted orphan drug designation to EDIT-301 for the potential treatment of

05-13 16:38

Editas Medicine granted Orphan Drug Designation for beta thalassemia candidate

The U.S. FDA has granted Orphan Drug designation to Editas Medicine (NASDAQ:EDIT) for EDIT-301, its candidate for beta thalassemia. The company is planning to dose the first person in a phase 1/2 tria

05-13 06:03

Editas Medicine Shares Tick Down 1.5% on EDIT-301 FDA Designation

By Denny Jacob Editas Medicine Inc. shares fell 1.5% to $10.65 in after-hours trading Thursday after it said the Food and Drug Administration granted EDIT-301 orphan drug designation. EDIT

05-13 05:29

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational,

05-13 04:41

Morgan Stanley Lowers Editas Medicine's Price Target to $15 From $17, Underweight Rating Kept

12:45 PM EDT, 05/09/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co

05-10 00:59

Expert Ratings for Editas Medicine

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 1 2 0 Last 30D 0 0 0

05-10 00:10